New promising prostate cancer vaccine

At the prostate cancer symposium in Orlando,than 200,000 new cases are discovered every year.
co-sponsored by the American Society of ClinicalMost of the patients can follow a treatment based
Oncology, Eric J. Small, MD, UCSF professor ofon surgery, radiation and hormone therapy, but
medicine and urology presented the findings of theasymptomatic metastatic HRPC is known to be
study he led helped by other 19 US institutions,resistant to hormone therapy and every year more
regarding an effective treatment for prostate cancer.than 30,000 men die because and no other
The study was made on patients with asymptomatictreatment is effective against the disease.
metastatic hormone refractory prostate cancerPhilip Kantoff of the Dana-Farber Cancer Center in
(HRPC) and was designed for observing if theBoston was delighted to hear about the discovery
disease progression will be delayed and patients willbut said that the findings need to be confirmed.
survive longer.In order to do so, Dendreon Corp. of Seattle (the
Scientists said that the rate of survival increased bydeveloper of the vaccine) has begun another study
four and a half months in those who wereon 98 men with advanced prostate cancer and so far
administered the cancer vaccine compared withthe results seem to be confirming the discovery, said
those who got the placebo.Mitchell H. Gold, the company's president and chief
The vaccine was well tolerated by patients and theexecutive. If in the end the results are promising, the
side effects were mild: fever and chills. This is goodcompany could ask for the approval of the FDA. The
news because chemotherapy gives a lot ofcompany wants to see the treatment's effects on
unbearable side effects.patients with earlier stages of prostate cancer too,
Scientists did not find out for how long thedeclared Mitchell Gold.
treatment will hold the cancer in check, but JamieThis vaccine does not shrink the tumor yet, but as
Bearse of the National Prostate Cancer Coalition saidlong as it generates a good enough immune response
that as long as there are so few options regardingit can be very useful to patients. This trial was an
treating prostate cancer, this is quite an encouragingimportant one because it opened the way to other
result and hope still exists.treatments regarding prostate cancer.
In US, prostate cancer is quite common and more